A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/38 (2006.01) A61K 31/00 (2006.01) A61K 31/192 (2006.01) A61K 31/381 (2006.01)
Patent
CA 2157798
Retinoid-like compounds which act as agonists of the RXR retinoid receptor sites induce apoptosis of tumor cells in cell cultures, and are used as drugs to treat tumors in mammals including humans. Compounds which are specific agonists of RXR receptors and also compounds which are agonists of both RAR and RXR agonist (pan-agonists) induce apoptosis, although the RXR agonist compounds are preferred as drugs to avoid undesirable side effects associated with RAR agonist activity. The RXR agonists compounds are administered to mammals afflicted with tumors in pharmaceutical adapted for systemic topical or for intralesional administration. The range of concentration of the active ingredient RXR agonist compound in the pharmaceutical compositions is approximately between 0.001 and 5 percent by weight, and such that the composition delivers approximately 0.1 mg to 100 mg of the active ingredient per kg body weight of the patient, per day of treatment.
Chandraratna Roshantha A.
Davies Peter A. J.
Allergan Inc.
Gowling Lafleur Henderson Llp
The Board Of Regents Of The University Of Texas System
LandOfFree
Treatment of tumors with compounds having rxr retinoid... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of tumors with compounds having rxr retinoid..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of tumors with compounds having rxr retinoid... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1684893